BCRP9

Across TCGA pan-cancer cohorts, BCRP9 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of BCRP9’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where BCRP9 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types BCRP9 is over-expressed in tumor, although a few such as KIRC show the opposite, repressed pattern.

HNSC, LUSC, and KIRC are the cancer types where BCRP9 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BCRP9 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	III,IV	+1.279	<.001	12	view →
LUSC	Male	All	+1.178	<.001	5	view →
KIRC	All	All	−0.041	.024	4	view →
UCEC	All	IV	+0.640	.028	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

BCRP9–HNSC

Open the HNSC breakdown →